Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.28 USD
Change Today 0.00 / 0.00%
Volume 1.3M
IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Snapshot

Open
$14.24
Previous Close
$14.28
Day High
$14.88
Day Low
$14.02
52 Week High
07/17/15 - $19.43
52 Week Low
12/23/14 - $5.34
Market Cap
1.2B
Average Volume 10 Days
1.4M
EPS TTM
$-0.70
Shares Outstanding
87.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOGEN INC (IMGN)

immunogen inc (IMGN) Related Businessweek News

No Related Businessweek News Found

immunogen inc (IMGN) Details

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugates technology. It offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. The company’s clinical stage anticancer compounds include IMGN853 for the treatment of ovarian cancer, endometrial cancer, and other cancers, as well as IMGN529 and coltuximab ravtansine for the treatment of diffuse large B-cell lymphoma and other B-cell malignancies; and preclinical stage compounds comprise IMGN779 for the treatment of acute myeloid leukemia and myelodysplastic syndrome. It also develops BT-062 for multiple myeloma; BAY 94-9343 for mesothelioma and ovarian cancers; SAR650984 that is in Phase II clinical trials for multiple myeloma; AMG 595, which is in Phase I clinical trials for glioblastoma; and SAR566658 Phase I clinical trials for CA6-positive solid tumors. In addition, the company develops AMG 172 that is in Phase I clinical trials for clear cell renal cell carcinoma; SAR408701, which is in Phase I clinical trials for CEACAM5-positive solid tumors; LOP628 that is in Phase I clinical trial for c-Kit-positive cancers; and PCA062, which is in Phase I clinical trial for P-cadherin-positive cancers. ImmunoGen, Inc. has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; Sanofi; and Takeda, as well as research agreement with CytomX Therapeutics to develop probody-drug conjugates against a specified number of cancers. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

317 Employees
Last Reported Date: 08/27/15
Founded in 1981

immunogen inc (IMGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $544.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $245.0K
Chief Development Officer and Executive Vice ...
Total Annual Compensation: $432.4K
Executive Vice President of Distinguished Res...
Total Annual Compensation: $377.2K
Compensation as of Fiscal Year 2014.

immunogen inc (IMGN) Key Developments

Immunogen Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2015; Provides Earnings Guidance for the Fiscal Year Ending June 30, 2016

ImmunoGen announced unaudited consolidated earnings results for the fourth quarter and full year ended June 30, 2015. For the quarter, the company reported total revenue of $12,611,000 compared to $5,743,000 a year ago. Loss from operations was $25,087,000 compared to $26,500,000 a year ago. Net loss was $30,474,000 or $0.35 per share basic and diluted compared to a net loss of $26,499,000 or $0.31 per share basic and diluted for the same quarter of last year. For fiscal year ended June 30, 2015, the company reported total revenue of $85,541,000 compared to $59,896,000 a year ago. Loss from operations was $54,455,000 compared to $71,531,000 a year ago. Net loss was $60,739,000 or $0.71 per share basic and diluted compared to $71,364,000 or $0.83 per share basic and diluted for fiscal 2014. Cash used in operations was $55.3 million and capital expenditures totaled $7.4 million in fiscal 2015. For the fiscal year ending June 30, 2016, the company expects revenues between $70 million and $80 million; operating expenses to be between $175 million and $180 million; and net losses between $120 million and $125 million; cash used in operations to be between $100 million and $105 million; capital expenditures to total between $13 million and $15 million.

ImmunoGen, Inc. Presents at UBS SMID Cap One-on-One Conference, Aug-04-2015

ImmunoGen, Inc. Presents at UBS SMID Cap One-on-One Conference, Aug-04-2015 . Venue: Boston Harbor Hotel, 70 Rowes Wharf, Boston, MA 02110, United States. Speakers: Carol Hausner, Executive Director of Investor Relations & Corporate CommunicationS, Charles Q. Morris, Chief Development Officer and Executive Vice President, Sarah Kiely.

ImmunoGen, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 01:00 PM

ImmunoGen, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 01:00 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Daniel M. Junius, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $14.28 USD 0.00

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €12.52 EUR -0.07
Abzena PLC 71.00 GBp 0.00
BioInvent International AB kr2.80 SEK +0.01
Kyowa Hakko Kirin Co Ltd ¥2,065 JPY +53.00
MorphoSys AG €62.74 EUR -1.20
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 35.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit www.immunogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.